Biocaptiva raises £2.1m in seed financing to advance clinical trials for its cancer biopsy device.
The funding round was led by Archangels to support human trials of the BioCaptis device.
Share allotment filed at Companies House
Biocaptiva is a Scottish medical technology company developing the BioCaptis device to capture cell-free DNA for cancer management.
Biocaptiva has secured £2.1m in an additional seed financing round to advance its liquid biopsy technology through initial human trials. The investment was led by Archangels, with participation from Scottish Enterprise, Cancer Research Horizon, and Old College Capital.
The capital will finance the company through its first human trials for the BioCaptis device, which are expected to yield initial data by the end of 2022. The funding also supports preparations for regulatory trials scheduled to commence in 2023.
From the founder
"BIOCAPTIVA is at the forefront of developing technology to transform liquid biopsy testing in cancer management. We are pleased to have raised these additional funds as the company enters its next stage of development, with the BioCaptis beginning its first in human trials. These trials will allow us to generate important data before the end of 2022. This will be a key step before starting regulatory trials in 2023 as we move towards our goal of unleashing the full potential of liquid biopsy in cancer management to improve patient outcomes."
Jeremy Wheeler
CEO at Biocaptiva
Investor perspective
"In 2021, Archangels supported the spin-out of BIOCAPTIVA from the University of Edinburgh based on the technology developed from Professor Tim Aitman and Professor Mark Bradley’s research. Since then, the company has made remarkable progress and is poised to begin the first in-human trials with BioCaptis just over a year after its formation. We are pleased to lead this financing to support the company in generating its first in human data, and towards its ambition of ensuring that the BioCaptis device can play a key role in realizing the full potential of liquid biopsy testing for cancer management."
Sarah Hardy
Head of New Investments and Director, Archangels
Use of funds
- 01Fund research and development
- 02Build out infrastructure
Investors
Categories
About the company
Biocaptiva
Biocaptiva develops technology designed to improve liquid biopsy testing for cancer management.